Tesamorelin: One Small Change to a Natural Hormone
Hormonal, Growth Hormone & Body Composition Research
Tesamorelin is a modified version of a hormone your body already makes. The natural molecule, growth hormone releasing hormone, is broken down in circulation within minutes. Tesamorelin is that same sequence with one structural change designed to slow the breakdown down — and that change is essentially the whole point of the compound.
View product →Findings
- Tesamorelin is a natural human hormone (GHRH) with one structural change that stops it breaking down within minutes.
- It acts at the same receptor as the natural hormone, but persists long enough to study.
- Tesamorelin has a genuine pharmaceutical history.
- Once mixed, its working window is days rather than weeks; plan handling around that.
The problem tesamorelin was built to solve
Growth hormone releasing hormone (GHRH) signals the pituitary to release growth hormone. As a research tool it has an awkward property: an enzyme called DPP-4 clips it almost immediately, which makes the native peptide difficult to study over any useful interval.
Tesamorelin is GHRH(1–44) carrying an added trans-3-hexenoyl group at one end. That addition obstructs the enzymatic cleavage site, so the molecule persists longer than the unmodified hormone while acting at the same receptor.
This is a recurring pattern in peptide research: take an endogenous signalling molecule, make a small structural modification that resists degradation, and you get something you can actually run an experiment with.
How it differs from the secretagogues
Tesamorelin and compounds like ipamorelin both end up influencing growth hormone signalling, but they arrive by different routes. Tesamorelin is a GHRH analogue — it acts at the GHRH receptor. Secretagogues such as ipamorelin act at the ghrelin receptor instead.
Because the two receptor pathways are distinct, researchers frequently examine them side by side, or in combination, rather than treating them as substitutes. If you are working in this area, the CJC-1295 + Ipamorelin blend covers the other half of that comparison.
Form and handling
Tesamorelin is supplied as a lyophilised powder in a sealed vial. Like most peptides in this class it is reconstituted in a laboratory setting with bacteriostatic water and kept refrigerated and shielded from light thereafter. The dry vial is the stable form; once in solution, the clock starts.
Purity and documentation
Tesamorelin is a 44-residue peptide, one of the longer sequences in the research catalogue, so the certificate of analysis is a useful reference: it records the identity and purity of the material, established analytically. Certificates of analysis from independent laboratories are published for each compound, with purity above 99 percent.
Vistara Labs material is third-party tested, and the published certificates are on the lab reports page.
Buying tesamorelin in Canada
Every order ships from within Canada, so there is no customs step and transit stays short, which suits a lyophilised product that is kept dry until it reaches the lab. Current sizing and pricing are on the tesamorelin product page, the full range is in the peptide catalogue, and questions are welcome at any time.
Sourcing note: researchers looking to buy tesamorelin in Canada can read our Tesamorelin buying guide for domestic-stock, purity and shipping details.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
References
Tesamorelin has been studied in randomised placebo-controlled trials measuring body composition and liver fat directly.
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionRandomised placebo-controlled trial with safety extension; 404 people with HIV-associated abdominal fat accumulation.
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trialRandomised, double-blind, multicentre trial in people with HIV and non-alcoholic fatty liver disease, 12 months.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
